Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,market,currency,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,marketState,exchange,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,gmtOffSetMilliseconds,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,shortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry,address2
t0,IGXT,-3041000.0,149294000,471000,,-2261000,,-2261000,929000,-335000,-1927000,-1927000,,-334000,,,,0,286000,2213000,621000,-334000,,-2261000,-2261000,48662000.0,13286000.0,-3041000.0,145000.0,10245000.0,1000.0,206000.0,-50812000.0,-892000.0,255000.0,1572000.0,5817000.0,1553000.0,-892000.0,6437000.0,3553000.0,406000.0,1083000.0,6928000.0,120000.0,1949000.0,627000.0,-251000.0,615000.0,1257000.0,1257000.0,202000.0,367000.0,-36000.0,-1469000.0,192000.0,126000.0,238000.0,285000.0,-12000.0,,-2264000.0,en-US,US,EQUITY,False,Delayed Quote,us_market,USD,-0.078942455,0,PRE,PNK,False,False,0.42095,1630525898,0.02094999,0.405,0.4369,0.405,164553,42.095,-15.59074,15,America/New_York,EDT,4,5.2374973,0.405 - 0.4369,0.4,0.0,0.0,0,0,finmb_30124036,Other OTC,IntelGenx Technologies Corp.,USD,197143,83628,0.30095,2.5079167,0.12 - 0.69,-0.26905,-0.38992754,0.12,0.69,1616688301,1636541940,1636977600,-0.062,0.01,-14400000,-0.027,0.40771428,0.013235718,0.03246322,0.45702899,-0.03607899,62845308,INTELGENX TECHNOLOGIES CORPORAT,2.72,,,0.69,0.12,0.4077,0.457,197.14k,83.63k,149.29M,,83.05M,34.60%,0.00%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-371.01%,-32.90%,,1.63M,0.01,41.60%,1.54M,-5.29M,-6.85M,-0.0620,,1.98M,0.02,11.19M,,0.61,-0.03,-5.07M,-3.6M,Value,H4S 1Y2,Healthcare,"IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.",Montreal,514 331 7440,QC,1609372800,Canada,http://www.intelgenx.com,86400,6420 Abrams,514 331 0436,Biotechnology,Ville Saint Laurent
t-1,IGXT,-953000.0,149294000,337000,,-1277000,,-1277000,1228000,790000,-973000,-973000,,-321000,,,,0,790000,1763000,0,-304000,,-1277000,-1277000,48453000.0,12071000.0,-953000.0,166000.0,11118000.0,1000.0,407000.0,-48551000.0,-856000.0,252000.0,1205000.0,4368000.0,2047000.0,-856000.0,6561000.0,4305000.0,1038000.0,1249000.0,7137000.0,244000.0,1989000.0,227000.0,-420000.0,205000.0,1304000.0,1242000.0,153000.0,868000.0,-68000.0,-511000.0,198000.0,45000.0,365000.0,425000.0,-22000.0,-62000.0,-63000.0,en-US,US,EQUITY,False,Delayed Quote,us_market,USD,-0.078942455,0,PRE,PNK,False,False,0.42095,1630525898,0.02094999,0.405,0.4369,0.405,164553,42.095,-15.59074,15,America/New_York,EDT,4,5.2374973,0.405 - 0.4369,0.4,0.0,0.0,0,0,finmb_30124036,Other OTC,IntelGenx Technologies Corp.,USD,197143,83628,0.30095,2.5079167,0.12 - 0.69,-0.26905,-0.38992754,0.12,0.69,1616688301,1636541940,1636977600,-0.062,0.01,-14400000,-0.027,0.40771428,0.013235718,0.03246322,0.45702899,-0.03607899,62845308,INTELGENX TECHNOLOGIES CORPORAT,2.72,,,0.69,0.12,0.4077,0.457,197.14k,83.63k,149.29M,,83.05M,34.60%,0.00%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-371.01%,-32.90%,,1.63M,0.01,41.60%,1.54M,-5.29M,-6.85M,-0.0620,,1.98M,0.02,11.19M,,0.61,-0.03,-5.07M,-3.6M,Value,H4S 1Y2,Healthcare,"IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.",Montreal,514 331 7440,QC,1609372800,Canada,http://www.intelgenx.com,86400,6420 Abrams,514 331 0436,Biotechnology,Ville Saint Laurent
t-2,IGXT,-87000.0,149294000,848000,,-1660000,,-1660000,869000,510000,-1389000,-1389000,,-274000,,,,0,510000,1899000,0,-271000,,-1660000,-1660000,48051000.0,10680000.0,-87000.0,195000.0,10593000.0,1000.0,,-47274000.0,-865000.0,737000.0,337000.0,4667000.0,2126000.0,-865000.0,6355000.0,3501000.0,1194000.0,1494000.0,5538000.0,279000.0,2212000.0,1868000.0,369000.0,1851000.0,-59000.0,-59000.0,-58000.0,203000.0,-40000.0,-1549000.0,182000.0,99000.0,-599000.0,118000.0,-17000.0,-62000.0,-1166000.0,en-US,US,EQUITY,False,Delayed Quote,us_market,USD,-0.078942455,0,PRE,PNK,False,False,0.42095,1630525898,0.02094999,0.405,0.4369,0.405,164553,42.095,-15.59074,15,America/New_York,EDT,4,5.2374973,0.405 - 0.4369,0.4,0.0,0.0,0,0,finmb_30124036,Other OTC,IntelGenx Technologies Corp.,USD,197143,83628,0.30095,2.5079167,0.12 - 0.69,-0.26905,-0.38992754,0.12,0.69,1616688301,1636541940,1636977600,-0.062,0.01,-14400000,-0.027,0.40771428,0.013235718,0.03246322,0.45702899,-0.03607899,62845308,INTELGENX TECHNOLOGIES CORPORAT,2.72,,,0.69,0.12,0.4077,0.457,197.14k,83.63k,149.29M,,83.05M,34.60%,0.00%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-371.01%,-32.90%,,1.63M,0.01,41.60%,1.54M,-5.29M,-6.85M,-0.0620,,1.98M,0.02,11.19M,,0.61,-0.03,-5.07M,-3.6M,Value,H4S 1Y2,Healthcare,"IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.",Montreal,514 331 7440,QC,1609372800,Canada,http://www.intelgenx.com,86400,6420 Abrams,514 331 0436,Biotechnology,Ville Saint Laurent
t-3,IGXT,1434000.0,149294000,602000,,-1650000,,-1650000,1016000,42000,-1751000,-1751000,,-300000,,,,0,42000,1793000,0,101000,,-1650000,-1650000,48003000.0,10134000.0,1434000.0,,11568000.0,1000.0,,-45614000.0,-956000.0,720000.0,134000.0,4106000.0,1942000.0,-956000.0,6404000.0,4444000.0,2953000.0,847000.0,5537000.0,370000.0,2026000.0,1450000.0,63000.0,1426000.0,45000.0,-24000.0,1000.0,-221000.0,-83000.0,-1540000.0,175000.0,-6000.0,45000.0,-168000.0,-24000.0,-69000.0,338000.0,en-US,US,EQUITY,False,Delayed Quote,us_market,USD,-0.078942455,0,PRE,PNK,False,False,0.42095,1630525898,0.02094999,0.405,0.4369,0.405,164553,42.095,-15.59074,15,America/New_York,EDT,4,5.2374973,0.405 - 0.4369,0.4,0.0,0.0,0,0,finmb_30124036,Other OTC,IntelGenx Technologies Corp.,USD,197143,83628,0.30095,2.5079167,0.12 - 0.69,-0.26905,-0.38992754,0.12,0.69,1616688301,1636541940,1636977600,-0.062,0.01,-14400000,-0.027,0.40771428,0.013235718,0.03246322,0.45702899,-0.03607899,62845308,INTELGENX TECHNOLOGIES CORPORAT,2.72,,,0.69,0.12,0.4077,0.457,197.14k,83.63k,149.29M,,83.05M,34.60%,0.00%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-371.01%,-32.90%,,1.63M,0.01,41.60%,1.54M,-5.29M,-6.85M,-0.0620,,1.98M,0.02,11.19M,,0.61,-0.03,-5.07M,-3.6M,Value,H4S 1Y2,Healthcare,"IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.",Montreal,514 331 7440,QC,1609372800,Canada,http://www.intelgenx.com,86400,6420 Abrams,514 331 0436,Biotechnology,Ville Saint Laurent
